文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽1的血管舒张作用在肥胖伴血管胰岛素抵抗人类的骨骼肌和心肌微血管中保留,但在传导动脉中不保留

Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance.
PubMed 文献 · Diabetes Care · 2019-12-30

研究纳入15名肥胖成人,比较生理盐水与GLP-1输注(1.2 pmol/kg/min,150分钟)加或不加正常血糖胰岛素钳夹对微血管的影响。胰岛素未能改变骨骼肌或心肌微血管血容量或血流,证实微血管胰岛素抵抗;GLP-1单独输注使骨骼肌和心肌微血管血容量分别增加约30%和约40%,血流速度无变化。叠加胰岛素未进一步增加微血管血容量或血流,但使稳态葡萄糖输注率增加约20%。

要点

  • 肥胖伴微血管胰岛素抵抗者中,GLP-1保留骨骼肌和心肌微血管舒张作用。
  • GLP-1使骨骼肌和心肌微血管血容量分别增加约30%和约40%,血流速度无变化。
  • GLP-1联合胰岛素使稳态葡萄糖输注率增加约20%,微血管血容量或血流未进一步增加。

核心结论

  • 在伴微血管胰岛素抵抗的肥胖人类中,GLP-1的血管舒张作用在骨骼肌和心肌微血管中均保留,可能有助于改善代谢性胰岛素反应和心血管结局。

研究设计与样本

  • 研究纳入15名肥胖成人,受试者接受静脉输注生理盐水或GLP-1(1.2 pmol/kg/min)150分钟,并在最后120分钟叠加或不叠加正常血糖胰岛素钳夹(1 mU/kg/min)。
  • 测定骨骼肌和心肌微血管血容量、血流速度和血流、肱动脉直径和血流以及脉搏波速度。

主要发现

  • 胰岛素未能改变骨骼肌或心肌的微血管血容量或血流,证实存在微血管胰岛素抵抗。
  • GLP-1单独输注使骨骼肌和心肌微血管血容量分别增加约30%和约40%,血流速度无变化,导致骨骼肌和心肌微血管血流显著增加。
  • 在GLP-1输注基础上叠加胰岛素未进一步增加骨骼肌或心肌的微血管血容量或血流,但使稳态葡萄糖输注率增加约20%。
  • 胰岛素、GLP-1及GLP-1联合胰岛素输注均未改变肱动脉直径和血流或脉搏波速度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND METHODS: Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS: Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ∼30% and ∼40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ∼20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS: In obese humans with microvascular insulin resistance, GLP-1's vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wang N, Tan AWK, Jahn LA, et al. Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance. Diabetes Care. 2019. PMID: 31888883. doi:10.2337/dc19-1465

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。